Clinical trials: DASATINIB
Chronic Myelogenous Leukemia
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
- Trial name
- NCT03216070
- Testing
- Dasatinib 50 MG
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Two types are embryonal RMS (ERMS) and alveolar RMS (ARMS). Dasatinib may block over-expression of a certain enzyme.
- Conditions
- Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
- Trial name
- NCT03041701
- Testing
- Dasatinib, Ganitumab
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART B (NCT05751044)
- Testing
- Dasatinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Diffuse Intrinsic Pontine Glioma
Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
- Trial name
- NCT00996723
- Testing
- vandetanib and dasatinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed AML, T(8;21)
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled.
- Conditions
- Relapsed AML, T(8;21), C-KIT Mutation
- Trial name
- NCT03560908
- Testing
- Dasatinib
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
The main aim of the present study is to evaluate the clinical efficacy of first-line dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic leukemia.
- Trial name
- ALL (NCT01004497)
- Testing
- Dasatinib, Cyclophosphamide, Vincristine
- Where
- 8 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- The Catholic University of Korea
B Acute Lymphoblastic Leukemia
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia…
- Trial name
- NCT06124157
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy
- Where
- 161 sites in United States, Australia and 2 more
- Volunteers
- 222 people
- Sponsor
- National Cancer Institute (NCI)
Myelogenous Leukemia, Chronic, Chronic Phase
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission(CMR) while on…
- Trial name
- NCT01887561
- Testing
- dasatinib
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kanto CML Study Group
Advanced Cancer
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer.
- Trial name
- NCT01015222
- Testing
- Dasatinib, Bevacizumab, Paclitaxel
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
The purpose of this clinical research study was to establish a recommended phase 2 once daily (QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous…
- Trial name
- NCT00306202
- Testing
- Dasatinib
- Where
- 13 sites in Austria, France and 4 more
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of dasatinib and temsirolimus when given together with cyclophosphamide in treating patients with solid tumors that have spread to other places in the body, have come…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
- Trial name
- NCT02389309
- Testing
- Cyclophosphamide, Dasatinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00036738
- Testing
- Cyclosporine, Dasatinib, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study
This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days.
- Trial name
- PASS (NCT02546791)
- Testing
- Dasatinib
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
- Trial name
- NCT06390319
- Testing
- Dexamethasone, Vincristine, Daunorubicin
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
Glioma, High Grade Glioma
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)…
- Conditions
- Glioma, High Grade Glioma, Pontine Tumors
- Trial name
- NCT03352427
- Testing
- Dasatinib, Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Myeloid Leukemia
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of imatinib mesylate.
- Trial name
- NCT00866736
- Testing
- dasatinib
- Where
- Japan
- Volunteers
- 65 people
- Sponsor
- Kanto CML Study Group
Pineoblastoma
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
Children, adolescents and young adults with relapsed or treatment refractory pineoblastoma (rPB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not available.
- Trial name
- NCT02596828
- Testing
- Temozolomide, Irinotecan, Dasatinib
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- University of Regensburg
Lung Cancer, Non-Small Cell Lung Cancer
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors.
- Trial name
- NCT00826449
- Testing
- Dasatinib, Erlotinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Expanded Access for Dasatinib
This is an expanded access designed to provide access to dasatinib for eligible participants.
- Trial name
- NCT00454753
- Testing
- Dasatinib
- Sponsor
- Bristol-Myers Squibb